|
NR 1-2/2004
SUPLEMENT
|
|
|
|
|
|
|
|
|
Przeciwciała
przeciwko beta-2 glikoproteinie I w surowicy i cieczy wodnistej
chorych na jaskrę i zaćmę
Serum and aqueous humor anti
beta-2 glikoprotein I antibodies in patients with glaucoma and
cataract
Małgorzata Latalska1, Marek
Gerkowicz1, Ewa Kosior-Jarecka2, Maria
Kozioł-Montewka2, Małgorzata Pietraś-Trzpiel1
1Z II Kliniki Okulistyki Akademii Medycznej im. prof.
Feliksa Skubiszewskiego w Lublinie
Kierownik: dr hab. n. med. Marek Gerkowicz
2Z Katedry i Zakładu Mikrobiologii Lekarskiej
Akademii Medycznej im. prof. Feliksa Skubiszewskiego w Lublinie
Kierownik: prof. dr hab. n. med. Maria Kozioł-Montewka |
|
|
| Summary: |
Purpose: Evaluation
of the serum and aqueous humor antibodies to beta-2
glikoprotein I in patients with glaucoma.
Material and methods: 48 persons (38 women and 17
men), aged 30-86 (mean age 70), suffering from glaucoma
was examined. There were 19 with POAG, 18 with PACG and
11 with PEXG. All patients have undergone
trabeculectomia.
The group of 20 operated patients, because of
age-related cataracta (7 men and 13 women), aged 47-82 (mean
age 65), constituted a control group. All patients
agreed with samples collection. In plasma and anterior
chamber fluid, the level of antibodies to b-2
glicoprotein I classes IgA and IgG were measured using
ELISA method (commercial kits produced by Euroimmun),
according to producer's instruction. Statistical
analysis was performed using U Mann-Whitney test when
both groups were compared and Spearman test to
comparisons concerning single group.
Results: Significant changes between glaucoma and
cataract patients were observed in anty-b-2 glicoprotein
I antibodies class IgA in aqeuous humour (p=0,04) and in
serum (p= 0,03).
Conclusions: Knowledge of the immunological
pathogenesis in the glaucomatous nerve damage can be
curtailed or even prevented with the use of proper
agents. Indeed, there are many intriguing new
therapeutic possibilities on the horizon. To determine
the clinical potential of serum antibodies in glaucoma
patients, a randomized clinical trial would be necessary.
It is the preliminary communication. |
| Słowa kluczowe: |
jaskra, przeciwciała anty
beta-2 glikoproteinie I, surowica, ciecz wodnista. |
| Key words: |
glaucoma, antibodies to
beta-2 glikoprotein I, serum, aqueous humor. |
|
|
|
|
|
|
